REGENXBIO/$RGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Ticker
$RGNX
Sector
Primary listing
Employees
371
Headquarters
Website
REGENXBIO Metrics
BasicAdvanced
$467M
-
-$3.76
1.13
-
Price and volume
Market cap
$467M
Beta
1.13
52-week high
$16.19
52-week low
$5.81
Average daily volume
864K
Financial strength
Current ratio
2.382
Quick ratio
2.272
Long term debt to equity
206.967
Total debt to equity
253.587
Interest coverage (TTM)
-3.58%
Profitability
EBITDA (TTM)
-145.583
Gross margin (TTM)
-45.86%
Net profit margin (TTM)
-113.75%
Operating margin (TTM)
-94.58%
Revenue per employee (TTM)
$460,000
Management effectiveness
Return on assets (TTM)
-21.93%
Return on equity (TTM)
-107.00%
Valuation
Price to revenue (TTM)
2.735
Price to book
4.48
Price to tangible book (TTM)
4.48
Price to free cash flow (TTM)
-3.689
Free cash flow yield (TTM)
-27.11%
Free cash flow per share (TTM)
-2.45
Growth
Revenue change (TTM)
104.54%
Earnings per share change (TTM)
-18.05%
3-year revenue growth (CAGR)
14.78%
10-year revenue growth (CAGR)
36.50%
3-year earnings per share growth (CAGR)
-16.67%
10-year earnings per share growth (CAGR)
3.78%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Business Wire·10 hours ago
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp·10 hours ago
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
Business Wire·12 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $467M as of April 15, 2026.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of April 15, 2026.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of April 15, 2026.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.